Rafferty Asset Management, LLC - TRAVERE THERAPEUTICS INC ownership

TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 177 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.28 and the average weighting 0.3%.

Quarter-by-quarter ownership
Rafferty Asset Management, LLC ownership history of TRAVERE THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$1,498,440
-67.3%
182,292
-69.4%
0.01%
-64.7%
Q1 2024$4,589,239
+18.9%
595,232
+38.7%
0.02%
+6.2%
Q4 2023$3,858,157
+19.2%
429,161
+18.6%
0.02%
-15.8%
Q3 2023$3,236,217
-57.7%
361,993
-27.3%
0.02%
-55.8%
Q2 2023$7,653,151
+4.2%
498,252
+52.6%
0.04%
-14.0%
Q1 2023$7,342,310
+9.3%
326,470
+2.2%
0.05%
-10.7%
Q4 2022$6,718,118
+32.5%
319,454
+55.3%
0.06%
+3.7%
Q3 2022$5,070,000
+57.1%
205,767
+54.5%
0.05%
+80.0%
Q2 2022$3,228,000
-22.3%
133,225
-17.4%
0.03%
+20.0%
Q1 2022$4,155,000
-22.8%
161,243
-6.9%
0.02%
-10.7%
Q4 2021$5,379,000
+122.0%
173,286
+73.4%
0.03%
+64.7%
Q3 2021$2,423,000
+23.3%
99,922
-25.8%
0.02%
+41.7%
Q2 2021$1,965,000
-19.6%
134,661
+37.6%
0.01%
-29.4%
Q1 2021$2,444,000
+717.4%
97,878
+792.3%
0.02%
+466.7%
Q4 2020$299,00010,9690.00%
Other shareholders
TRAVERE THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Finepoint Capital LP 1,026,300$21,5836.98%
Deep Track Capital, LP 4,582,000$96,359,4604.05%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 379,019$7,963,1892.46%
ARMISTICE CAPITAL, LLC 6,412,000$134,844,3602.35%
GREAT POINT PARTNERS LLC 475,000$9,989,2501.96%
RA Capital Management 3,984,681$83,797,8411.70%
MPM BioImpact LLC 281,711$5,924,3821.54%
HighVista Strategies LLC 121,834$2,562,1691.52%
Kynam Capital Management, LP 418,099$8,792,6221.35%
SECTORAL ASSET MANAGEMENT INC 292,320$6,147,4901.19%
View complete list of TRAVERE THERAPEUTICS INC shareholders